Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
205.9 USD | +1.68% | +6.21% | -20.21% |
Apr. 25 | Biogen Inc. Receives Positive CHMP Opinion for TOFIDence (tocilizumab), a Biosimilar Referencing ROACTEMRA | CI |
Apr. 25 | Goldman Sachs Adjusts Biogen Price Target to $340 From $393 | MT |
- Stock Market
- Equities
- BIIB Stock
- News Biogen Inc.